Expression of Viral Antigen by the Liver Leads to Chronic Infection Through the Generation of Regulatory T Cells

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 3, 2015, Pages 325-341.e1

  Lapierre, Pascal ^a   Janelle, Valérie ^a   Langlois, Marie Pierre ^a   Tarrab, Esther ^a   Charpentier, Tania ^a   Lamarre, Alain ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Chronic infection; Hepatitis; Tolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; CD4 ANTIGEN; CD8 ANTIGEN; INTERFERON; INTERLEUKIN 10; NUCLEOPROTEIN; PREALBUMIN; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; VIRUS ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENE SILENCING; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LIVER; LIVER CELL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE; VIRAL CLEARANCE;

EID: 84929241829     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.02.002     Document Type: Article

References (35)

1. Calne R.Y., Sells R.A., Pena J.R., et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969, 223:472-476.
2. Yang R., Liu Q., Grosfeld J.L., et al. Intestinal venous drainage through the liver is a prerequisite for oral tolerance induction. JPediatr Surg 1994, 29:1145-1148.
3. high phenotype, poor CTL function and cell death. JHepatol 2012, 57:830-836.
4. Protzer U., Maini M.K., Knolle P.A. Living in the liver: hepatic infections. Nat Rev Immunol 2012, 12:201-213.
5. Thimme R., Oldach D., Chang K.M., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. JExp Med 2001, 194:1395-1406.
6. Penaloza-MacMaster P., Kamphorst A.O., Wieland A., et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. JExp Med 2014, 211:1905-1918.
7. Crispe I.N. Immune tolerance in liver disease. Hepatology 2014, 60:2109-2117.
8. Djilali-Saiah I., Lapierre P., Vittozi S., et al. DNA vaccination breaks tolerance for a neo-self antigen in liver: a transgenic murine model of autoimmune hepatitis. JImmunol 2002, 169:4889-4896.
9. + T-cells encounter their cognate antigen and acquire capacity to destroy target hepatocytes. JAutoimmun 2013, 42:19-28.
10. + regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology 2010, 51:1789-1798.
11. Inaba K., Swiggard W.J., Steinman R.M., et al. Isolation of dendritic cells. Curr Protoc Immunol 2009, Chapter 3. Unit 3.7.
12. Muller U., Steinhoff U., Reis L.F., et al. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
13. Zhou S., Cerny A.M., Zacharia A., et al. Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus. JVirol 2010, 84:9452-9462.
14. + T cells. JImmunol 2005, 174:3377-3385.
15. + T cell immunodominance shifts during the early stages of acute LCMV infection independently from functional avidity maturation. Virology 2009, 390:197-204.
16. Schluns K.S., Kieper W.C., Jameson S.C., et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells invivo. Nat Immunol 2000, 1:426-432.
17. Tay S.S., Wong Y.C., McDonald D.M., et al. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc Natl Acad Sci USA 2014, 111:E2540-2549.
18. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
19. Doyle L.B., Doyle M.V., Oldstone M.B. Susceptibility of newborn mice with H-2k backgrounds to lymphocytic choriomeningitis virus infection. Immunology 1980, 40:589-596.
20. Kagi D., Ledermann B., Burki K., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37.
21. Louten J., van Rooijen N., Biron C.A. Type 1 IFN deficiency in the absence of normal splenic architecture during lymphocytic choriomeningitis virus infection. JImmunol 2006, 177:3266-3272.
22. Schildknecht A., Welti S., Geuking M.B., et al. Absence of CTL responses to early viral antigens facilitates viral persistence. JImmunol 2008, 180:3113-3121.
23. + T-cell tolerance induced by steady-state dendritic cells. Proc Natl Acad Sci U S A 2010, 107:199-203.
24. + Tregs and immune control. JClin Invest 2004, 114:1209-1217.
25. + regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40:1062-1071.
26. Kared H., Fabre T., Bedard N., et al. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013, 9:e1003422.
27. Park S.H., Veerapu N.S., Shin E.C., et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med 2013, 19:1638-1642.
28. + T regulatory cell subset in humans. JImmunol 2013, 190:2001-2008.
29. Akimova T., Beier U.H., Wang L., et al. Helios expression is a marker of T cell activation and proliferation. PLoS One 2011, 6:e24226.
30. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
31. Flynn J.K., Dore G.J., Hellard M., et al. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. JViral Hepat 2011, 18:549-561.
32. Moskophidis D., Lechner F., Pircher H., et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
33. Blattman J.N., Wherry E.J., Ha S.J., et al. Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. JVirol 2009, 83:4386-4394.
34. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. NEngl J Med 1998, 338:161-165.
35. Rech A.J., Vonderheide R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009, 1174:99-106.